Cargando…

Characteristics of Seizure and Antiepileptic Drug Utilization in Outpatients With Autoimmune Encephalitis

Autoimmune encephalitis (AE) is one kind of encephalitis that associates with specific neuronal antigens. Most patients with AE likely suffer from seizures, but data on the characteristics of seizure and antiepileptic drugs (AEDs) utilization in this patient group remains limited. This study aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Qi, Ma, Meigang, Wei, Xing, Liao, Yuhan, Qi, Hengchang, Wu, Yuejuan, Wu, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331521/
https://www.ncbi.nlm.nih.gov/pubmed/30671012
http://dx.doi.org/10.3389/fneur.2018.01136
_version_ 1783387150132183040
author Huang, Qi
Ma, Meigang
Wei, Xing
Liao, Yuhan
Qi, Hengchang
Wu, Yuejuan
Wu, Yuan
author_facet Huang, Qi
Ma, Meigang
Wei, Xing
Liao, Yuhan
Qi, Hengchang
Wu, Yuejuan
Wu, Yuan
author_sort Huang, Qi
collection PubMed
description Autoimmune encephalitis (AE) is one kind of encephalitis that associates with specific neuronal antigens. Most patients with AE likely suffer from seizures, but data on the characteristics of seizure and antiepileptic drugs (AEDs) utilization in this patient group remains limited. This study aimed to report the clinical status of seizure and AEDs treatment of patients with AE, and to evaluate the relationship between AEDs discontinuation and seizure outcomes. Patients with acute neurological disorders and anti-N-methyl-D-aspartate receptor (NMDAR), γ-aminobutyric acid B receptor (GABA(B)R), leucine-rich glioma inactivated 1, or contactin-associated protein-like 2 (CASPR2) antibodies were included. As patients withdrew from AEDs, they were divided into the early withdrawal (EW, AEDs used ≤3 months) and late withdrawal (LW, AEDs used >3 months) groups. Seizure remission was defined as having no seizures for at least 1 year after the last time when AEDs were administered. Seizure outcomes were assessed on the basis of remission rate. The factors affecting the outcomes were assessed through Spearman analysis. In total, we enrolled 75 patients (39 patients aged <16 years, male/female = 39/36) for follow-up, which included 67 patients with anti-NMDAR encephalitis, 4 patients with anti-GABA(B)R encephalitis, 2 patients with anti-voltage-gated potassium channel encephalitis, and 2 patients with coexisting antibodies. Among the 34 enrolled patients with anti-NMDAR encephalitis who were withdrawn from AEDs, only 5.8% relapse was reported during the 1-year follow-up, with no significant difference in the percentage of relapse between the EW and LW groups (P = 0.313). Fifteen patients (an average age of 6.8, 14 patients with anti-NMDAR encephalitis and 1 patient with anti-CASPR2 encephalitis) presented seizure remission without any AEDs. Seventy five percent of patients with anti-GABA(B)R antibodies developed refractory seizure. Other risk factors which contributed to refractory seizure and seizure relapse included status epilepticus (P = 0.004) and cortical abnormalities (P = 0.028). Given this retrospective data, patients with AE have a high rate of seizure remission, and the long-term use of AEDs may not be necessary to control the seizure. Moreover, seizures in young patients with anti-NMDAR encephalitis presents self-limited. Patients with anti-GABA(B)R antibody, status epilepticus, and cortical abnormalities are more likely to develop refractory seizure or seizure relapse.
format Online
Article
Text
id pubmed-6331521
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63315212019-01-22 Characteristics of Seizure and Antiepileptic Drug Utilization in Outpatients With Autoimmune Encephalitis Huang, Qi Ma, Meigang Wei, Xing Liao, Yuhan Qi, Hengchang Wu, Yuejuan Wu, Yuan Front Neurol Neurology Autoimmune encephalitis (AE) is one kind of encephalitis that associates with specific neuronal antigens. Most patients with AE likely suffer from seizures, but data on the characteristics of seizure and antiepileptic drugs (AEDs) utilization in this patient group remains limited. This study aimed to report the clinical status of seizure and AEDs treatment of patients with AE, and to evaluate the relationship between AEDs discontinuation and seizure outcomes. Patients with acute neurological disorders and anti-N-methyl-D-aspartate receptor (NMDAR), γ-aminobutyric acid B receptor (GABA(B)R), leucine-rich glioma inactivated 1, or contactin-associated protein-like 2 (CASPR2) antibodies were included. As patients withdrew from AEDs, they were divided into the early withdrawal (EW, AEDs used ≤3 months) and late withdrawal (LW, AEDs used >3 months) groups. Seizure remission was defined as having no seizures for at least 1 year after the last time when AEDs were administered. Seizure outcomes were assessed on the basis of remission rate. The factors affecting the outcomes were assessed through Spearman analysis. In total, we enrolled 75 patients (39 patients aged <16 years, male/female = 39/36) for follow-up, which included 67 patients with anti-NMDAR encephalitis, 4 patients with anti-GABA(B)R encephalitis, 2 patients with anti-voltage-gated potassium channel encephalitis, and 2 patients with coexisting antibodies. Among the 34 enrolled patients with anti-NMDAR encephalitis who were withdrawn from AEDs, only 5.8% relapse was reported during the 1-year follow-up, with no significant difference in the percentage of relapse between the EW and LW groups (P = 0.313). Fifteen patients (an average age of 6.8, 14 patients with anti-NMDAR encephalitis and 1 patient with anti-CASPR2 encephalitis) presented seizure remission without any AEDs. Seventy five percent of patients with anti-GABA(B)R antibodies developed refractory seizure. Other risk factors which contributed to refractory seizure and seizure relapse included status epilepticus (P = 0.004) and cortical abnormalities (P = 0.028). Given this retrospective data, patients with AE have a high rate of seizure remission, and the long-term use of AEDs may not be necessary to control the seizure. Moreover, seizures in young patients with anti-NMDAR encephalitis presents self-limited. Patients with anti-GABA(B)R antibody, status epilepticus, and cortical abnormalities are more likely to develop refractory seizure or seizure relapse. Frontiers Media S.A. 2019-01-08 /pmc/articles/PMC6331521/ /pubmed/30671012 http://dx.doi.org/10.3389/fneur.2018.01136 Text en Copyright © 2019 Huang, Ma, Wei, Liao, Qi, Wu and Wu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Huang, Qi
Ma, Meigang
Wei, Xing
Liao, Yuhan
Qi, Hengchang
Wu, Yuejuan
Wu, Yuan
Characteristics of Seizure and Antiepileptic Drug Utilization in Outpatients With Autoimmune Encephalitis
title Characteristics of Seizure and Antiepileptic Drug Utilization in Outpatients With Autoimmune Encephalitis
title_full Characteristics of Seizure and Antiepileptic Drug Utilization in Outpatients With Autoimmune Encephalitis
title_fullStr Characteristics of Seizure and Antiepileptic Drug Utilization in Outpatients With Autoimmune Encephalitis
title_full_unstemmed Characteristics of Seizure and Antiepileptic Drug Utilization in Outpatients With Autoimmune Encephalitis
title_short Characteristics of Seizure and Antiepileptic Drug Utilization in Outpatients With Autoimmune Encephalitis
title_sort characteristics of seizure and antiepileptic drug utilization in outpatients with autoimmune encephalitis
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331521/
https://www.ncbi.nlm.nih.gov/pubmed/30671012
http://dx.doi.org/10.3389/fneur.2018.01136
work_keys_str_mv AT huangqi characteristicsofseizureandantiepilepticdrugutilizationinoutpatientswithautoimmuneencephalitis
AT mameigang characteristicsofseizureandantiepilepticdrugutilizationinoutpatientswithautoimmuneencephalitis
AT weixing characteristicsofseizureandantiepilepticdrugutilizationinoutpatientswithautoimmuneencephalitis
AT liaoyuhan characteristicsofseizureandantiepilepticdrugutilizationinoutpatientswithautoimmuneencephalitis
AT qihengchang characteristicsofseizureandantiepilepticdrugutilizationinoutpatientswithautoimmuneencephalitis
AT wuyuejuan characteristicsofseizureandantiepilepticdrugutilizationinoutpatientswithautoimmuneencephalitis
AT wuyuan characteristicsofseizureandantiepilepticdrugutilizationinoutpatientswithautoimmuneencephalitis